Clinical Trial: BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Pancreatic Ductal Adenocarcinoma
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Brief Summary:
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Read more